Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,034 INR | +2.27% | +0.60% | +27.45% |
Apr. 09 | Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit | MT |
Mar. 27 | NATCO Pharma Limited Announces Board Appointments | CI |
Sales 2024 * | 39.19B 470M | Sales 2025 * | 45.13B 541M | Capitalization | 185B 2.22B |
---|---|---|---|---|---|
Net income 2024 * | 13.21B 158M | Net income 2025 * | 15.27B 183M | EV / Sales 2024 * | 4.33 x |
Net cash position 2024 * | 15.67B 188M | Net cash position 2025 * | 31.57B 378M | EV / Sales 2025 * | 3.4 x |
P/E ratio 2024 * |
14.1
x | P/E ratio 2025 * |
12.3
x | Employees | 3,946 |
Yield 2024 * |
0.97% | Yield 2025 * |
1.09% | Free-Float | 46.76% |
Latest transcript on NATCO Pharma Limited
1 day | +2.27% | ||
1 week | +0.60% | ||
Current month | +1.57% | ||
1 month | +4.09% | ||
3 months | +20.41% | ||
6 months | +39.07% | ||
Current year | +27.45% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 00-07-02 | |
Founder | 78 | 81-09-18 | |
Director of Finance/CFO | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 81-09-18 | |
Chief Executive Officer | 46 | 00-07-02 | |
Director/Board Member | 70 | 14-04-17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 4 M€ | -4.41% | - | |
0.01% | 117 M€ | +2.11% | - | |
0.00% | 34 M€ | +2.67% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 1,034 | +2.27% | 930,313 |
24-05-02 | 1,011 | -0.69% | 340,489 |
24-04-30 | 1,018 | +1.04% | 437,177 |
24-04-29 | 1,008 | -1.97% | 447,897 |
24-04-26 | 1,028 | +0.66% | 1,157,262 |
Delayed Quote NSE India S.E., May 03, 2024 at 07:43 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.45% | 2.22B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- NATCOPHARM Stock